<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Yeshwant Kurhe | Ruth Palmer Lab</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/author/yeshwant-kurhe/</link><atom:link href="https://deploy-preview-3--ruthpalmerlab.netlify.app/author/yeshwant-kurhe/index.xml" rel="self" type="application/rss+xml"/><description>Yeshwant Kurhe</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Tue, 02 Jan 2024 00:00:00 +0000</lastBuildDate><image><url>https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.png</url><title>Yeshwant Kurhe</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/author/yeshwant-kurhe/</link></image><item><title>ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/</link><pubDate>Tue, 02 Jan 2024 00:00:00 +0000</pubDate><guid>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/</guid><description/></item><item><title>ATR inhibition enables complete tumour regression in ALK-driven NB mouse models</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/</link><pubDate>Wed, 24 Nov 2021 00:00:00 +0000</pubDate><guid>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/</guid><description/></item></channel></rss>